USPTO serial 77112466
COLDSTREAM
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MIZELLE HOWARD, DEZMONA JULYE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with COLDSTREAM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kimberly Gambrel
Kimberly Gambrel DINSMORE & SHOHL LLPONE SOUTH MAIN STREET, SUITE 1300DAYTON, OH 45402-2023UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations, namely, anticoagulants, antidepressants, appetite suppressants, anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations, vaccines, antihelmintics and psychotropics; pharmaceutical preparations for the treatment of viral and infectious diseases; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations for use in dermatology, oncology and ophthalmology; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for ophthalmological use; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical antitussive-cold preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for wounds; pharmaceutical preparations for use in urology; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for gastroenterological disorders; pharmaceutical preparations for the treatment of diabetes; pharmaceutical products for the treatment of bone diseases; pharmaceutical solutions used in dialysis; pharmaceuticals, namely, lipid lowering agents; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, inducers of erections; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for chloasma; pharmaceutical skin lotions; pharmaceutical preparations for animal skincare | ACTIVE | — |
| 042 | research and development in the field of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Coldstream Laboratories, Inc.
- Other trademarks owned by Coldstream Laboratories, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named COLDSTREAM
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 21, 2009 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 21, 2009 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 8, 2009 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 8, 2009 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 20, 2009 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 20, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 29, 2008 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 29, 2008 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 29, 2008 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 20, 2008 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 26, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 6, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 22, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 22, 2008 | ALIE | ASSIGNED TO LIE | — |
| Dec 7, 2007 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 6, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 4, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 4, 2007 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 8, 2007 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 8, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 7, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 27, 2007 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Feb 26, 2007 | NWAP | NEW APPLICATION ENTERED | — |